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 Abstract—Cardiac 18F-FDG PET has been used in clinics 
to assess myocardial glucose metabolism. Its ability for 
imaging myocardial glucose transport, however, has rarely 
been exploited in clinics. Using the dynamic FDG-PET 
scans of ten patients with coronary artery disease, we 
investigate in this paper appropriate dynamic scan and 
kinetic modeling protocols for efficient quantification of 
myocardial glucose transport. Three kinetic models and the 
effect of scan duration were evaluated by using statistical fit 
quality, assessing the impact on kinetic quantification, and 
analyzing the practical identifiability. The results show that 
the kinetic model selection depends on the scan duration. 
The reversible two-tissue model was needed for a one-hour 
dynamic scan. The irreversible two-tissue model was 
optimal for a scan duration of around 10 minutes. If the 
scan duration was shortened to 2 minutes, a one-tissue 
model was the most appropriate. For global quantification 
of myocardial glucose transport, we demonstrated that an 
early dynamic scan with a duration of 10 minutes and 
irreversible kinetic modeling was comparable to the full 
one-hour scan with reversible kinetic modeling. Myocardial 
glucose transport quantification provides an additional 
physiological parameter on top of the existing assessment of 
glucose metabolism, which may be used as a surrogate of 
myocardial blood flow to enable single tracer 
multiparametric imaging in the myocardium. 
 
Index Terms—18F-FDG PET, dynamic imaging, myocardial 
viability, kinetic modeling, model selection, identifiability analysis, 
glucose transport, glucose metabolism. 
I. INTRODUCTION 
ositron emission tomography (PET) with the radiotracer 
18F-fluorodeoxyglucose (FDG) is broadly used for imaging 
glucose metabolism [1, 2]. In clinical cardiology, FDG-PET is 
mainly applied to assess myocardial viability, myocardial 
inflammation, and other cardiac inflammatory diseases (e.g., 
cardiac sarcoidosis) [3-5]. Hibernating myocardium consists of 
viable muscles that are characterized by a perfusion-
metabolism mismatch: low perfusion tracer uptake but high 
FDG uptake. In combination with PET perfusion imaging using 
a flow tracer such as 82Rb-chloride [6-10], 15O-water [11, 12], 
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or 13N-ammonia [8, 13], FDG-PET assessment of myocardial 
viability has become a valuable clinical tool to identify this 
mismatch [14]. Patients with coronary artery disease who have 
hibernating myocardium usually benefit from additional 
surgical revascularization [15]. 
Standard cardiac FDG-PET uses static scanning and provides 
standardized uptake value (SUV) for the characterization of 
myocardial glucose metabolism. Alternatively, dynamic FDG-
PET has also been investigated for quantitative myocardial 
imaging [16-18]. With compartmental modeling [19-22] or 
graphical analysis [23-27], most of these existing dynamic 
cardiac FDG-PET studies focused on quantitative evaluation of 
glucose metabolism. Nevertheless, the ability of dynamic FDG-
PET for assessing blood-to-myocytes glucose transport has 
rarely been exploited for clinical applications in cardiac 
imaging.  
We hypothesize that a glucose transport-metabolism 
mismatch exists in a hibernating myocardium, similar to the 
well-established flow-metabolism mismatch [3, 4]. The 
hypothesis is built upon the potential correlation between 
glucose transport and blood flow, which has been demonstrated 
for noncardiac tissues such as tumor [28-30] but not yet for the 
myocardium. Successful testing of this hypothesis may lead to 
a new and more accessible imaging solution using FDG-PET 
only to assess myocardial viability or inflammation without the 
need for a perfusion tracer. This FDG-only method has the 
potential to reduce imaging time, cost, and radiation exposure 
as compared to the traditional two-tracer methods (e.g., Rb-82 
PET plus FDG-PET) in clinical use today [31, 32]. 
The main purpose of this study was to establish an effective 
and efficient dynamic imaging and kinetic analysis approach to 
quantifying myocardial glucose transport from dynamic FDG-
PET in human patients. Standard dynamic FDG-PET scanning 
commonly lasts for one hour [33], and use both the irreversible 
and reversible two-tissue compartmental models for model 
selection with mixed results [22, 34]. In addition, the attention 
of these previous studies was mainly on the FDG net influx rate 𝐾! or the metabolic rate of glucose that characterize myocardial 
glucose metabolism [16-18, 22, 27], but not on glucose 
transport quantification.  
In this paper, we revisited the kinetic model selection for 
dynamic cardiac FDG-PET imaging using cardiac patient scans. 
In particular, we investigated the effect of scan duration on 
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model selection and its impact on quantification of myocardial 
kinetics with a focus on glucose transport quantification. A 
practical identifiability analysis was conducted to evaluate how 
reliable the myocardial kinetic parameters can be estimated. 
Our results provide supporting data and foundational protocols 
for the further testing of the myocardial glucose transport-
metabolism mismatch in future studies using FDG-PET only 
for evaluating myocardial viability. 
This paper is organized as follows. Section II describes the 
methods of dynamic FDG-PET data acquisition, kinetic 
modeling, model selection, and practical identifiability analysis 
for myocardial kinetic quantification. The results are then 
reported in Section III, followed by a detailed discussion of the 
findings and limitations of this study in Section IV. Finally, 
conclusions are drawn in Section V.  
II. METHODS 
A. Dynamic 18F-FDG PET/CT Data Acquisition 
Fourteen patients who were scheduled for PET myocardial 
viability assessment consented into this study. The study was 
approved by the Institutional Review Board at the University of 
California, Davis. Each patient in the study first received 
glucose and/or insulin administration following a standard 
clinical protocol to ensure the highest quality of images. 
Patients then underwent a dynamic FDG-PET/CT scan 
followed by a standard static FDG-PET/CT scan on a GE 
Discovery ST PET/CT scanner in two-dimensional mode. The 
center of the scanner axial field of view was positioned at the 
heart of each patient. Patients received approximately 20 mCi 
18F-FDG with bolus injection.  
For the dynamic PET scan, list-mode data acquisition 
commenced immediately following the FDG injection. A low-
dose transmission CT scan was performed before the dynamic 
PET scan for PET attenuation correction.  
The raw PET data were binned into a total of 49 dynamic 
frames: 30 × 10s, 10 × 60s, and 9 × 300s. Dynamic FDG-PET 
images were reconstructed using the standard ordered subsets 
expectation maximization (OSEM) algorithm with two 
iterations and 30 subsets as provided in the vendor software. 
Standard corrections for normalization, attenuation, dead-time, 
scatter, and random coincidences were applied. No motion 
correction was applied in this study. 
 
B. Kinetic Modeling of Dynamic Cardiac FDG-PET Data 
(1) Extraction of blood input functions and myocardial time 
activity curves (TACs). Two regions of interest (ROIs) were 
manually placed in the left ventricle (LV) and right ventricle 
(RV) to extract the image-derived blood input functions 𝐶"#(𝑡) 
and 𝐶$#(𝑡) in the unit of Bq/mL. An additional 17 ROIs were 
placed within the 17 segments of myocardium according to the 
AHA-17 standard [18]. These segment ROIs were combined 
into a global myocardial ROI and used to extract a global 
myocardial TAC 𝐶%(𝑡) using ROI mean. Due to high noise of 
the dynamic data in individual segments, the analysis of this 
study was focused on global myocardial quantification. 
(2) Full kinetic modeling. The reversible two-tissue (2T) 
compartmental model [35, 36] shown in Fig. 1 was first used to 
model the one-hour dynamic data. The corresponding ordinary 
differential equations of this 2T model are:  d𝐶&(𝑡)d𝑡 = 𝐾&𝐶"#(𝑡) − (𝑘' + 𝑘()𝐶&(𝑡) +	𝑘)𝐶'(𝑡), (1) d𝐶'(𝑡)d𝑡 = 𝑘(	𝐶&(𝑡) −	𝑘)𝐶'(𝑡), (2) 
where 𝐶&(𝑡) is the activity concentration of free FDG and 𝐶'(𝑡) 
is the activity concentration of metabolized tracer in the 
myocardium tissue space. 𝐾& (mL/g/min) is the rate of glucose 
transport from the plasma to the tissue space;  𝑘' (/min) is the 
rate constant of tracer exiting the tissue space;  𝑘( (/min) is the 
rate constant of FDG being phosphorylated;  𝑘) (/min) is the 
rate constant of FDG-6P being dephosphorylated.  
The total radioactivity that can be measured by PET is 
modeled as 𝐶%(𝑡; 𝜽) = 	 (1 −	𝑣"# − 𝑣$#)[𝐶&(𝑡) + 𝐶'(𝑡)]+𝑣"#𝐶"#(𝑡) +	𝑣$#𝐶$#(𝑡), (3) 
where 𝑣*+  and 𝑣,+  denote the fractional blood volume 
parameters attributed from the LV and RV, respectively. 𝜽 =[𝑣"#, 𝑣$#, 𝐾&, 𝑘', 𝑘(, 𝑘)]-  is a vector collecting all unknown 
parameters.  
The model parameters are estimated by fitting a measured 
myocardial TAC {𝐶7%(𝑡.)} using the following nonlinear least 
square estimation: 𝜽9 = argmin𝜽 𝑅𝑆𝑆(𝜽),	 (4) 𝑅𝑆𝑆(𝜽) = C 𝑤.E𝐶7%(𝑡.) − 𝐶%(𝑡.; 𝜽)F'0.1& , (5) 
where 𝑡. is the mid-point of the mth frame in a total of M time 
frames and 𝑤.  is the weighting factor. 𝑅𝑆𝑆(𝜽)  denotes the 
residual sum of squares of the curve fitting. The classic 
Levenberg-Marquardt algorithm with 100 iterations was used 
to solve the optimization problem in a way similar to our other 
work [37]. The fitting process was implemented using C/C++ 
programming. In this study, the initial value of 𝜽 was set to [0.1,0.1, 0.1, 0.1, 0.1, 0.001]-. The lower bound was zero and 
the upper bound was [1.0,1.0, 2.0, 2.0, 1.0, 0.1]-. 
For glucose transport quantification, the parameter of our 
interest is 𝐾&.  For glucose metabolism evaluation, the SUV at 
one-hour post-injection is a semi-quantitative measure. Hence, 
we also calculated the FDG net influx rate 𝐾!  from the 
estimated micro parameters using the form of: 
FDG in 
Plasma Cp(t)  
FDG in 
Myocytes C1(t) 
FDG -6P in 
Myocytes C2(t) 
𝐾!  
𝑘" 
𝑘# 
𝑘$ 
Figure 1: The reversible two-tissue compartment model for myocardial FDG 
kinetics. K1 is the glucose transport rate from plasma to cardiac myocytes and 
k2 is the transport rate from myocytes to plasma. FDG is phosphorylated by 
hexokinase in cells into FDG 6-phosphate with the rate k3 and the process can 
be reversible by the rate k4. The model becomes irreversible if k4=0. 
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𝐾! = 𝐾&𝑘(/(𝑘' + 𝑘() (6) 
to provide a quantitative measure of glucose metabolism.  
(3) Model selection. For analyzing the dynamic cardiac 
FDG-PET data, we compared three different tracer kinetic 
models as listed in Table 1 : (1) 2T6P – the reversible two-tissue 
(2T) model with all kinetic parameters [𝑣"#,  𝑣$#, 𝐾&, 𝑘', 𝑘(, 𝑘)] estimated, (2) 2T5P – the irreversible 2T model with 𝑘) =0 , i.e., the dephosphorylation process is neglected in the 
modeling, and (3) 1T4P - a simplified one-tissue (1T) model 
without modeling the phosphorylation and dephosphorylation 
processes. This 1T4P model is equivalent to the 2T model with 𝑘( = 0  and 𝑘) = 0 . Different models were compared for 
statistical fit quality using the Akaike information criteria (AIC) 
[38, 39], 
AIC = 𝑀 ln P𝑅𝑆𝑆𝑀 Q + 2𝑛 + 2𝑛(𝑛 + 1)𝑀 − 𝑛 − 1 , (7) 
where M denotes the number of time frames used in fitting and 
n denotes the total number of unknown parameters, as listed in 
Table 1 for different models. Here AIC was corrected for finite 
sample sizes due to the ratio  02 ≤ 40 . A lower AIC value 
indicates a better selection of models [40].  
(4) Effect of scan duration on model selection and kinetic 
quantification. In this study, we also investigated the effect of 
scan duration post tracer injection on kinetic model selection. 
The scan duration was varied from two minutes to one hour 
following the successive time frames used in the scanning 
protocol. For each scan duration, the three candidate models 
were compared for statistical fit quality evaluation using AIC. 
The impact on myocardial kinetic parameter quantification was 
evaluated as a function of scan duration. The kinetic parameters 𝐾&  and 𝐾!  estimated by 2T6P of the one-hour dynamic data 
were considered as the reference for the patient data.   
C. Practical Identifiability Analysis of Kinetic Quantification 
We conducted a practical identifiability analysis using the 
Monte Carlo simulation approach to estimate the statistical 
properties associated with myocardial kinetic estimation, in a 
way similar to our previous work [41].  
(1) Determination of the TAC noise level. The TAC noise 
level of the patient data in the myocardium is estimated using 
the noise model [42]: 
∆𝐶%(𝑡.) = 𝐶7%(𝑡.) −	𝐶%(𝑡.; 𝜽)𝛿. 	~	Gaussian	(0, 𝑆3) (8) 
where the normalized residual activity ∆𝐶%(𝑡.)  in the mth 
frame is calculated as the difference between the noisy 
measurement 𝐶7%(𝑡.) and the fitted value 𝐶%(𝑡.; 𝜽). 𝛿. is the 
frame-dependent SD after normalization following the widely 
used model, 
𝛿. =	\𝐶%(𝑡.; 𝜽) exp(𝜆𝑡.) /∆𝑡. (9) 
with 𝜆 = ln(2/𝑇&/') the decay factor, 𝑇&/'  (min) the half-life 
of the radiotracer, and ∆𝑡. the duration of each frame. 𝑆3 is the 
SD of the Gaussian distribution and is obtained by fitting the 
histogram of ∆𝐶%(𝑡.)  using the Gaussian distribution. 𝑆3𝛿. 
together represents the noise level in each time frame m.  
(2) Computer simulation. The estimated FDG kinetic 
parameter set 𝜽5  from the one-hour dynamic data with the 
2T6P model was taken as the nominal set of parameters for each 
patient. Together with the patient’s blood input function, the 
nominal parameter set was used to generate the noise-free 
myocardial TAC. Independently and identically distributed 
noise was then added to the noise-free TAC to generate N = 
1000 realizations of noisy TACs. The noisy TACs were then 
fitted to obtain the noisy estimates of the kinetic parameters.  
(3) Evaluation metrics. The normalized bias, standard 
deviation (SD), and root mean square error (RMSE) were 
calculated to evaluate the statistical properties of the kinetic 
parameter estimation, 
𝐵𝑖𝑎𝑠g𝜃i6j = 	𝑀𝑒𝑎𝑛g𝜃i6j −		𝜃65𝜃65 	 , (10) 
𝑆𝐷g𝜃i6j = 	 1𝜃65m 1𝑁 − 1CE𝜃i6 −𝑀𝑒𝑎𝑛g𝜃i6jF'721& 	 , (11) 
𝑀𝑆𝐸g𝜃i6j = 	m1𝑁Cp𝜃i6 −	𝜃65𝜃65 q'721& , (12) 
where 𝜃65  denotes the kth kinetic parameter in 𝜽5 . Mean(⋅) 
represents the mean value of the noisy kinetic parameter 
estimates 𝜃i6. The same simulation process was repeated for all 
the 10 patient data sets.   
III. RESULTS 
A. Patient Characteristics 
Ten out of 14 patients completed the one-hour scan. The 
remaining four patients had shorter scan duration, ranging from 
Table 1. List of different kinetic models that are studied in this paper for 
dynamic cardiac FDG-PET kinetic modeling 
 
Model 
Type 
Number of 
Unknown 
Parameters, n 
Kinetic Parameters 
to Be Estimated 
Fixed 
Parameters 
2T6P 6 𝑣!",  𝑣#", 𝐾$, 𝑘%, 𝑘&, 𝑘' N/A 
2T5P 5 𝑣!",  𝑣#", 𝐾$, 𝑘%, 𝑘& 𝑘' = 0 
1T4P 4 𝑣!",  𝑣#", 𝐾$, 𝑘% 𝑘& = 0, 𝑘' = 0 
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30-45 minutes, because patients experienced discomfort. In this 
work, we only included the ten patients who underwent the 
complete one-hour dynamic scan for the data analysis. Of the 
ten patients, two were female (patient index #4 and #13 in figure 
3) and three were diabetic (#1, #8, #13). Patients had age of 
67±10 years in the range of 57-83 years, blood sugar level of 
106±9 mg/dL in the range of 84-135 mg/dL, and body mass 
index of 30±5 kg/m2 in the range of 22-39 kg/m2.  
B. Examples of TAC Fitting  
Figure 2 shows an example of measured global myocardial 
TAC of a patient with the error bars denoting the standard 
deviation of ROI activity quantification across the 17 segments 
in the myocardium. Figure 2(a) shows the fitting of the global 
myocardial TAC for the full one-hour data. The fitted TAC 
using the 2T6P model matched well with the noisy TAC. Figure 
2(b) and 2(c) respectively show the fitting for the early-dynamic 
TAC of 10 minutes using the 2T5P model and the early-
dynamic TAC of 120 seconds using the 1T4P model. All 
demonstrated good fitting in the respective time period.  
 
C. AIC Comparison of Kinetic Models for the One-hour Data 
 To evaluate the quantitative measure of statistical TAC 
fitting quality, the AIC differences between 2T6P and 2T5P or 
1T4P are plotted in Fig. 3(a) for the one-hour data for all ten 
applicable patients. A positive AIC difference indicates that the 
2T6P model provides a better TAC fitting quality than the 2T5P 
or 1T4P model, and vice versa for a negative value of AIC 
difference. In 8 out of 10 patients, the 2T6P model 
outperformed the 2T5P and 1T4P models. The 1T4P model and 
the 2T5P model were only favored in one patient. The 
comparison result demonstrated that 2T6P is an appropriate 
model in most of the patients for fitting the one-hour global 
TAC data.  
 
D. Effect of Scan Duration on Model Selection 
Figure 3(b-c) shows the percentage of patients whose TAC 
fitting preferred the 2T6P, 2T5P, and 1T4P models as a function 
of scan duration. The scan duration varied from one hour to 2 
minutes. In the range from 10 to 60 minutes, the 2T6P model 
was generally favored in 70-80% patients. As the scan duration 
was reduced to 3-10 minutes, the 2T6P model was decreasingly 
preferred and the 2T5P became more appropriate for fitting the 
TACs. When the scan duration was further reduced to 2-3 
minutes, the 1T4P model was preferred for TAC fitting for most 
patients.  
 
E. Impact on Myocardial Kinetic Quantification 
Figure 4(a) shows how the myocardial FDG 𝐾&  values 
estimated by the 1T4P, 2T5P, and 2T6P models change as a 
function of the scan duration varying from 2 minutes to one 
hour in one example patient. Figure 4(b) summarizes the results 
from all the ten patients. Using 𝐾& of 2T6P from the full one-
                                             (a)                                                                                (b)                                                                                (c) 
  
Figure 2. Example of global myocardial TAC fitting. (a) Fitting of a one-hour TAC with the 2T6P model; (b) Fitting of a 10min TAC using the 2T5P model; (c) 
Fitting of a 120s TAC using the 1T4P model.  
 
 
                                              (a)                                                                                   (b)                                                                             (c) 
 
 
Figure 3. Comparison of different kinetic models using AIC. (a) AIC comparison in ten out of 14 patients that are applicable for this analysis. A positive AIC 
difference indicates that the 2T6P model provides a better TAC fitting quality than the comparison model; (b-c) Plots of the percentage of patients favoring a 
kinetic model over other models as a function of scan duration which varies from 2 minutes to one hour (b) and the zoom-in plots for the first 10 minutes (c). 
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hour data as the reference, the 𝐾&  estimation with the 2T6P 
model increasingly deviates as the scan duration is shortened. 
The difference in 𝐾& exceeded 5% once the scan duration was 
shorter than 30 minutes.  
The plots in Figure 4(a) and 4(b) also show that the use of the 
2T5P model for the one-hour data resulted in a more than 20% 
underestimation in 𝐾&  as compared to the reference value, 
indicating that neglecting k4 can actually affect the estimation 
of 𝐾&. However, at short scan durations the error in 𝐾& by the 
2T5P model decreases as the scan duration increases and 
reaches its minimum 2% at around 10-12 minutes.  
The 𝐾&  estimated by 1T4P significantly deviated from the 
reference 𝐾& when the duration was longer than 3-4 minutes, 
mainly due to the neglect of the phosphorylation parameters (𝑘( 
and/or 𝑘)) in the 1T4P. The mean absolute difference in 𝐾& 
from 1T4P decreases as the scan duration increases and reaches 
its minimum 10% around 2-3 minutes. 
Figure 4(c) shows the mean absolute difference for 𝐾! 
quantification by the different models. Again, the full one-hour 
data with the 2T6P model was used to provide the reference 𝐾! 
value in each patient. Note that the 1T4P model cannot be used 
to quantify 𝐾! . Overall, the effect of scan duration on 𝐾! 
quantification was very similar to that of 𝐾&. But the error from 
the 2T5P model was larger, over 50% for the full one-hour data 
and 8% for the shortened scan of 10-12 minutes. 
 
F. Identifiability Analysis for FDG 𝐾& Quantification 
Figure 5 shows the histogram of the normalized residual 
activities from the dynamic FDG-PET scans of 10 patients. The 
histogram was well-matched with the zero-mean Gaussian with 
a standard deviation of 𝑆3  = 0.3. Hence, we used 𝑆3  = 0.3 to 
simulate noisy TACs in the practical identifiability analysis 
unless specified otherwise. 
Figure 6 shows the plots of the bias and SD of 𝐾&  as a 
function of scan duration for different models. The results here 
were averaged across multiple patients. Overall, the SD of 𝐾& 
estimated by different models generally followed the same 
trend – decreasing scan duration increases the SD. The 
minimum SD of 2T5P was lower than that of 2T6P (10% vs. 
12%) because a smaller number of unknown parameters were 
estimated in the former model, which is associated with lower 
uncertainty. The 1T4P model led to a further reduction in the 
SD as compared to 2T5P and 2T6P.  
The bias of 𝐾& , however, behaved very differently in the 
three different models. The bias of 𝐾&  by 2T6P gradually 
increased from 3% to 9% as the scan duration decreased from 
one hour to 2 minutes. In comparison, the bias of 𝐾& by 2T5P 
was 20% at one hour but decreased as the scan duration was 
shortened to 10 minutes where the bias reached its minimum of 
3%. The bias then increased as the scan duration continued to 
decrease. The bias of 𝐾& by the 1T4P model was nearly 50% 
with the one-hour scan duration and gradually decreased to 6% 
as the scan duration was shortened to 2 minutes.  
The changing trend on the bias of 𝐾& from this simulation 
study is consistent with the patient data presented in figure 3 
and figure 4.  
 
G. Identifiability Analysis for Other Kinetic Parameters 
Figure 7 shows the mean absolute bias and SD of FDG 𝐾! for 
the 2T6P and 2T5P models. The 1T4P model cannot be used to 
provide 𝐾! estimation. The trend of the change in 𝐾! was very 
similar to that of 𝐾&  in each of the two kinetic models. The 
minimum bias of 𝐾! was 4% by the 2T6P model but about 50% 
by the 2T5P model, indicating that the 2T5P model might be 
                                                (a)                                                                                (b)                                                                             (c) 
 
 
Figure 4. Effect of scan duration on myocardial kinetic estimation in different kinetic models. (a) Plots of 𝐾! as a function of scan duration for different kinetic 
models for one example patient; (b) Mean absolute difference in 𝐾! quantification as compared to the reference 𝐾! values. The mean difference was calculated 
over 10 patients. (c) Mean absolute difference in 𝐾" quantification as compared to the reference 𝐾" values. 
 
 
 
Figure 5. Histogram of normalized residual activity ∆𝐶# from the dynamic 
FDG-PET scans of 14 patients and a fit with the Gaussian distribution.  
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inappropriate for accurate 𝐾! quantification in the myocardium. 
The 2T6P and full one-hour data are instead required.  
Table 2 summarizes the mean absolute bias, SD, and RMSE 
of multiple kinetic parameters estimated from the 2-minute 
(2M) early dynamic scan with the 1T4P model, the 10-minute 
(10M) early-dynamic data with the 2T5P model, and the 1-hour 
(1H) dynamic data with the 2T6P model. The three protocols 
represent the appropriately optimal option for a short, medium, 
and long scan duration. For 𝐾& quantification, the 2T5P-10M 
protocol achieved similar bias, SD and RMSE as compared to 
the full 2T6P-1H protocol. While the 1T4P-2M protocol had a 
2 times higher bias, the bias still remained below 10%. For 𝐾! 
quantification, the 2T5P protocol did not show comparable 
performance. The bias was nearly 3 times the bias of the 2T6P-
1H protocol for 𝐾!.  
Table 2 also shows the results for other parameters including 𝑘', 𝑘(, and 𝑘). The bias and SD of 𝑘( are generally higher than 
that of 𝐾& and 𝐾!, indicating it is less stable for clinical use. 
 
H. Effect of Noise Level 
 Fig. 8 shows the patient-averaged bias and SD of FDG 𝐾& as 
a function of the noise level 𝑆3 for the 2T6P-1H, 2T5P-10M, 
and 1T4P-2M protocols. For the GE Discovery ST scanner that 
we used in this patient study, the noise level in the global 
myocardium corresponds to 𝑆3 = 0.3 and the noise level in the 
myocardial segments of the AHA 17-segment model 
appropriately corresponds to 𝑆3 = 1.0. For the 2T6P-1H, as the 
noise level increases, both the bias and SD increase in 𝐾& 
quantification. At a low noise level (𝑆3 =0.3), 𝐾& had a bias of 
3%. At the high noise level 𝑆3 = 1.0, the bias of 𝐾& became 
over 15%.  The 𝐾& derived by 2T5P-10M had a slightly better 
Table 2. Mean absolute bias, SD, and RMSE of different kinetic parameters 
estimated by different kinetic models in all patients. 2M, 10M, and 1H refer 
to 2 minutes, 10 minutes, and 1 hour, respectively. 
 
KINETIC 
PARAMETER 
MODEL & 
TIME BIAS (%) SD (%) RMSE (%) 
𝐾! 1T4P, 2 M 6.2 17.0 18.9 2T5P, 10 M 3.1 12.6 13.2 
2T6P, 1 H 3.0 12.0 12.6 
𝐾" 1T4P, 2 M / / / 2T5P, 10 M 13.9 20.9 28.1 
2T6P, 1 H 3.9    17.0 17.6 
𝑘$ 1T4P, 2M 12.5 29.0 34.3 2T5P, 10M 5.0 15.7 16.9 
2T6P, 1H 4.0    14.6 15.4 
𝑘% 1T4P, 2M / / / 2T5P, 10M 17.2 28.8 36.2 
2T6P, 1H 6.5 27.2 28.2 
𝑘& 1T4P, 2M / / / 2T5P, 10M / / / 
2T6P, 1H 3.4 21.5 22.0 
 
                                           (a)                                                                                (b)                                                                                (c) 
 
 
Figure 6. Plots of the mean absolute bias and SD of 𝐾! as a function of scan duration for three different kinetic models: (a) 2T6P, (b) 2T5P, and (c)	1T4P. The 
1T4P model cannot be used to estimate a 𝐾". The scan duration is varied from 2 minutes to one hour. The mean bias and SD were calculated from ten applicable 
patients.  
                                                                                  (a)                                                                                    (b) 
     
 
Figure 7. Plots of the mean absolute bias and SD of 𝐾" as a function of scan duration for two different kinetic models: (a) 2T6P and (b) 2T5P. The scan duration 
is varied from 2 minutes to one hour.  
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bias curve than the 2T6P-1H. Because of model mismatch, the 
1T4P-2M protocol had higher bias for all noise levels. 
The SD of 𝐾& quantification with 2T6P-1H was 12% at the 
low noise level of 𝑆3 = 0.3 and 40% at the high noise level of  𝑆3 = 1.0 . The 2T5P-10M protocol achieved a very similar 
noise performance as the 2T6P-1H protocol, though the 1T4P-
2M protocol was associated with higher SD at all noise levels.  
The bias and SD results indicate the performance of 2T5P-10M 
is comparable to that of 2T6P-1H for FDG 𝐾& quantification, 
while the 1T4P-2M protocol is less similar. 
IV. DISCUSSION 
In this paper, we investigated tracer kinetic modeling 
strategies for dynamic cardiac FDG-PET for kinetic 
quantification of myocardial kinetics with emphasis on glucose 
transport. Both the reversible and irreversible two-tissue 
models were used in previous studies [22, 34]. However, the 
majority of existing dynamic cardiac FDG-PET focused on 
glucose metabolism (𝐾!) evaluation [16-18, 22, 27, 43], few on 
glucose transport (𝐾&) evaluation. The results from our study 
indicate that the reversible model (2T6P) is preferred for 
accurate modeling of one-hour dynamic cardiac FDG-PET data 
in humans (Fig. 3 and Fig. 4), suggesting that the 
dephosphorylation process (i.e., nonzero k4) is non-negligible 
in kinetic modeling of one-hour dynamic cardiac FDG-PET 
data. The bias and SD associated with 2T6P of one-hour data 
were about 3% and 12% for global myocardial 𝐾& 
quantification, and 4% and 17% for global 𝐾!  quantification, 
respecitvely (Table 2).  
When analyzing the one-hour dynamic data, the use of the 
irreversible model (2T5P) could result in a large bias in FDG 𝐾! (up to 50%) for glucose metabolism evaluation (Fig. 7b) and 
in FDG 𝐾& (up to 20%) for glucose transport evaluation (Fig. 
6b). The 𝐾!  results from 2T5P and 2T6P in figure 7 are 
consistent with general consensus that a more complex model 
is more accurate (lower bias) but can be less stable (higher SD), 
see [44] for an example in cardiac imaging. 
However, the irreversible model can become increasing 
accurate for FDG 𝐾&  quantification if the scan duration is 
reduced from one hour to about 10 minutes (Fig. 6b). The 
estimation of the dephosphorylation rate k4 becomes negligible 
for the shortened scan duration. The associated bias and SD 
with 𝐾& quantification was 3% and 13% (Table 2), respectively, 
which are comparable to the accuracy achieved by the 2T6P of 
the one-hour data. This suggests it is possible to quantify 𝐾& 
accurately without using a one-hour scan duration but a much-
shortened scan with an appropriate kinetic model. 
When the scan duration is further reduced to 2-3 minutes, the 
1T4P model can become appropriate (Fig. 3(c) and Fig. 6(c)), 
though is associated with a non-negligible bias in FDG 𝐾& 
(~6%) (Fig. 6c and Table 2). These results on 2T6P, 2T5P, and 
1T4P confirmed that the kinetic model selection depends on the 
scan duration of dynamic PET imaging. 
The finding on the 𝐾& quantification accuracy of the 2T5P 
model along with a scan duration of about 10 minutes is 
significant and can guide our future protocol designs for testing 
and applying single-tracer multiparametric imaging in clinics. 
FDG 𝐾&  can be used as a potential surrogate of myocardial 
blood flow for simultaneous flow-metabolism evaluation or is 
used directly for evaluating a transport-metabolism 
relationship. There are potentially two implementation options. 
The first option is to use the full one-hour dynamic FDG 
scanning, which can provide both 𝐾&  and 𝐾!  using the 2T6P 
model. A potential benefit of this protocol is that quantitative 𝐾!  is potentially more beneficial than the semi-quantitative 
SUV for the characterization of myocardial glucose 
metabolism. The disadvantage is that compared to standard 
static scanning, the prolonged dynamic scan duration not only 
increases the scan cost but also may result in compromised 
dynamic image quality or image degradation due to patient 
movement during the long scan.  
The other option is to add an early-dynamic scan of about 10 
minutes right after the FDG injection. This add-on scan 
protocol is only used for FDG 𝐾& quantification. Evaluation of 
myocardial glucose metabolism is still achieved using the 
standard clinical protocol, i.e., static scanning to provide a late-
time SUV usually at 75-95 minutes post-injection. One 
potential advantage of this protocol is it would only occupy an 
additional scanner time of 10 minutes and allow the same 
scanner to be used for other patients in between the two scans. 
                                                                          (a)                                                                                                       (b) 
     
 
Figure 8. Plots of patient-averaged bias and standard deviation (SD) of myocardial FDG 𝐾! as a function of noise level 𝑆' for the 2T6P-1H, 2T5P-10M, and 
1T4P-2M protocols. (a) Bias in percentage; (b) SD in percentage.  
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This study has several limitations. While our ultimate goal is 
to develop a single tracer multiparametric imaging method 
using tracer kinetic modeling, this work only focused on the 
first technical step to identify the appropriate method and 
protocol for kinetic quantification without directly evaluating 
the impact for clinical assessment. The limitations also include 
that we did not have a ground truth for the kinetic parameter 
quantification, although this is a general challenge for any study 
using patient data. We instead used the estimates of the 2T6P 
model from the full one-hour dynamic data as the reference. To 
validate the findings of the patient study, we had further 
conducted a computer simulation study to analyze the 
identifiability of the kinetic model parameters. 
The analysis of this study was limited to evaluation of global 
myocardial quantification, not investigating quantification at 
the level of myocardial segments or parametric imaging. In the 
disease cohort, a global myocardial TAC can be a mix of normal 
and abnormal tissue signals, thus neglecting the potential wide 
physiological heterogeneity. The major reason that we did not 
include segment-level investigation was the dynamic data of 
segments in this study are very noisy. The scanner used in this 
study is relatively old (2002 GE Discovery ST model) with no 
time-of-flight (TOF) capability and as a result, noise 
performance was far from optimal for exploring quantification 
in myocardial segments. The result from the practical 
identifiability analysis indicates it is less reliable to do FDG 𝐾& 
quantification in individual myocardial segments as the 
resulting bias and SD are high (Fig. 8; corresponding to 𝑆3 =1.0).  
The study did not consider motion correction, which could 
affect the accuracy of kinetic quantification [45-48]. 
Nevertheless, the effect of motion is not expected to result in a 
significant change to the results of this study since the spatial 
resolution of the PET scanner is only about 6-8 mm and the 
quantification was performed on large, global ROIs.  
There are a number of options to address the limitations of 
the study in our future work. Compared to the GE Discovery 
ST scanner used in this study,  latest scanners (e.g., Siemens 
Biograph Vision [49], GE Discovery MI [50]) have much 
higher scanner sensitivity which, together with time-of-flight 
capability, may reduce the noise at the myocardial segmental 
level from 𝑆3 = 1.0 to 𝑆3 = 0.3 or lower to allow FDG kinetic 
quantification in individual segments. The improved spatial 
resolution can also justify the increasing need for motion 
correction. In particular, the UIH uEXPLORER total-body 
PET/CT scanner [51, 52] has further improved sensitivity that 
may make it feasible to implement parametric imaging [53] in 
the myocardium. In addition, the images were reconstructed 
using standard vendor reconstruction in this study. Improved 
image reconstruction has been developed for dynamic PET 
imaging [53, 54] with the kernel methods [55, 56] as one of 
recent examples. Thus, our future work will explore the use of 
the latest PET/CT scanners and/or advanced image 
reconstruction to improve data quality for segment-level and 
voxel-wise kinetic quantification in the myocardium.  
V. CONCLUSIONS 
In tracer kinetic modeling of dynamic cardiac FDG-PET, 
optimal kinetic model selection depends on scan duration. The 
reversible two-tissue model, irreversible two-tissue model, and 
simplified one-tissue model are respectively appropriate for 
analyzing dynamic FDG imaging with a scan duration of about 
one-hour, 10 minutes, and less than 3 minutes. An early 
dynamic scan of about 10 minutes with irreversible kinetic 
modeling can be comparable to the full one-hour scan with 
reversible kinetic modeling for the evaluation of glucose 
transport rate 𝐾&  in the myocardium. Our future work will 
further improve the technical method and compare FDG 𝐾& to 
myocardial blood flow using patient data.  
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